Ashburn, VA, United States of America

Okponanabofa Eradiri

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Okponanabofa Eradiri: Innovator in Pharmaceutical Technology

Introduction

Okponanabofa Eradiri is a notable inventor based in Ashburn, VA (US). He has made significant contributions to the field of pharmaceutical technology, particularly in the development of modified-release medications. His innovative work has led to the creation of a patented formulation that enhances the delivery of bupropion hydrochloride.

Latest Patents

Eradiri holds a patent for a modified-release tablet of bupropion hydrochloride. This formulation comprises a core that includes an effective amount of bupropion hydrochloride, a binder, and a lubricant. Surrounding this core is a control-releasing coat, which is further encased in a moisture barrier. The modified-release tablet is designed to be bioequivalent to Wellbutrin® or Zyban®/Wellbutrin® SR tablets, providing an effective treatment option for patients.

Career Highlights

Eradiri is currently associated with Biovail Laboratories International S.r.l., where he continues to work on innovative pharmaceutical solutions. His expertise in drug formulation and delivery systems has positioned him as a valuable asset in the industry.

Collaborations

Throughout his career, Eradiri has collaborated with several professionals, including Werner Oberegger and Fang Zhou. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Okponanabofa Eradiri's contributions to pharmaceutical technology through his innovative patent demonstrate his commitment to improving patient care. His work continues to influence the field and offers promising solutions for medication delivery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…